These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22949142)

  • 41. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldosterone antagonists in heart failure.
    Miller SE; Alvarez RJ
    J Cardiovasc Nurs; 2013; 28(6):E47-54. PubMed ID: 23001067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.
    Pitt B
    Heart Fail Clin; 2012 Apr; 8(2):247-53. PubMed ID: 22405664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
    Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
    Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapy update. Inspra (eplerenone tablets).
    Kloner RA
    Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
    [No Abstract]   [Full Text] [Related]  

  • 46. [Study of the month. The RALES study (randomized aldactone evaluation study].
    Kulbertus H
    Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
    J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 52. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of heart failure treatment.
    Guyatt GH; Devereaux PJ
    Mt Sinai J Med; 2004 Jan; 71(1):47-54. PubMed ID: 14770250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Modern therapy of cardiac insufficiency].
    Stojsić D; Jelkić N
    Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New aldosteron receptor inhibitors in heart failure.
    Mandolini C; Vacca K; Borgia MC
    Minerva Cardioangiol; 2005 Aug; 53(4):241-8. PubMed ID: 16177669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of the RALE study. Hyperkalemia following spironolactone treatment].
    Erdmann E
    Internist (Berl); 2005 Apr; 46(4):466, 468. PubMed ID: 15723149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.